The conference brings together more than 50 of the world’s leading companies in the industry for presentations, debates and discussions. Dr. David Bonner, CEO of Regenetech, Regenetech presented the recent progress in the conference. The company in the fourth quarter of 2007, announced 60 – fold expansion of hematopoietic stem cells, as well as the signing of two international licenses for its technology cellXpansion.
Thought-provoking and at the 3rd Annual Stem Cell Summit in New Yorkadult Regenetech , Inc., the tissue regeneration, stem cell company that has built for NASA licensed technology, is pleased to announce that it will be sponsoring and presented at the 3rd Annual Stem Cell Summit in New York on 26 February 2008.Qnexa is well as the phase 2 clinical development for the treatment of type 2 diabetes. In the area of sexual health, VIVUS is in Stage 3 develop with Avanafil , a potentially best – in-class PDE5 inhibitor is, and in phase 2 the development of of the Luramist for the treatment of hypoactive sexual desire disorder in females. VUS , include but are treatment for treatment of ED, is already commercially available and generating revenue on VIVUS.. Over VIVUSVIVUS being a biopharmaceutical company that develops novel, next-generation therapy in order to tackle unmet needs the obesity, diabetic and sexual health. The company lead product in clinical trials, Qnexa has recently completed the Phase 3 clinical trials to the treatment of obesity.